AU2016309815B2 - Methods of treatment or prevention of acute brain or nerve injuries - Google Patents

Methods of treatment or prevention of acute brain or nerve injuries Download PDF

Info

Publication number
AU2016309815B2
AU2016309815B2 AU2016309815A AU2016309815A AU2016309815B2 AU 2016309815 B2 AU2016309815 B2 AU 2016309815B2 AU 2016309815 A AU2016309815 A AU 2016309815A AU 2016309815 A AU2016309815 A AU 2016309815A AU 2016309815 B2 AU2016309815 B2 AU 2016309815B2
Authority
AU
Australia
Prior art keywords
posiphen
acute brain
injury
acute
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016309815A
Other languages
English (en)
Other versions
AU2016309815A1 (en
Inventor
Maria Maccecchini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Annovis Bio Inc
Original Assignee
Annovis Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annovis Bio Inc filed Critical Annovis Bio Inc
Publication of AU2016309815A1 publication Critical patent/AU2016309815A1/en
Assigned to ANNOVIS BIO, INC. reassignment ANNOVIS BIO, INC. Amend patent request/document other than specification (104) Assignors: QR PHARMA
Application granted granted Critical
Publication of AU2016309815B2 publication Critical patent/AU2016309815B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016309815A 2015-08-14 2016-08-12 Methods of treatment or prevention of acute brain or nerve injuries Active AU2016309815B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562205431P 2015-08-14 2015-08-14
US62/205,431 2015-08-14
PCT/US2016/046794 WO2017030968A1 (en) 2015-08-14 2016-08-12 Methods of treatment or prevention of acute brain or nerve injuries

Publications (2)

Publication Number Publication Date
AU2016309815A1 AU2016309815A1 (en) 2018-02-15
AU2016309815B2 true AU2016309815B2 (en) 2022-04-07

Family

ID=56801810

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016309815A Active AU2016309815B2 (en) 2015-08-14 2016-08-12 Methods of treatment or prevention of acute brain or nerve injuries

Country Status (9)

Country Link
US (2) US12042482B2 (enExample)
EP (1) EP3334425B1 (enExample)
JP (1) JP6862446B2 (enExample)
CN (1) CN107921024B (enExample)
AU (1) AU2016309815B2 (enExample)
CA (1) CA2994974C (enExample)
DK (1) DK3334425T3 (enExample)
TW (1) TW201717938A (enExample)
WO (1) WO2017030968A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201717938A (zh) 2015-08-14 2017-06-01 Ｑｒ製藥股份有限公司 治療或預防急性腦部或神經損傷的方法
EP3654957A4 (en) 2017-05-24 2021-06-23 Annovis Bio, Inc. PREVENTION OR TREATMENT OF DISEASE CONDITIONS DUE TO METAL DIS-HOMEOSTASIS BY ADMINISTERING POSIPHES TO HEALTHY OR SICK PEOPLE

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171750A (en) 1991-09-26 1992-12-15 The United States Of America As Represented By The Department Of Health And Human Services Substituted phenserines as specific inhibitors of acetylcholinesterase
US5409948A (en) 1992-11-23 1995-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating cognitive disorders with phenserine
WO1999002154A1 (en) 1997-07-09 1999-01-21 Axonyx Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
DE60124730T2 (de) 2000-03-03 2007-10-04 Eisai R&D Management Co., Ltd. Neue methoden unter verwendung von cholinesteraseinhibitoren
WO2002048150A2 (en) 2000-11-02 2002-06-20 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
US6495700B1 (en) 2002-01-09 2002-12-17 Axonyx, Inc. Process for producing phenserine and its analog
US20040024043A1 (en) 2002-03-22 2004-02-05 Nigel Greig Method for treating cognitive disorders
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
EP1617844A4 (en) 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
US20050013869A1 (en) 2003-07-18 2005-01-20 Chaw Cheng Shu Sustained release formulation for carbamates and a method therefor
US20050182044A1 (en) 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
WO2005091987A2 (en) 2004-03-19 2005-10-06 Axonyx, Inc. Method of treating down syndrome
WO2005089746A1 (en) 2004-03-19 2005-09-29 Axonyx, Inc. Dosage titration for treatment of cognitive disorders
EP1604686A1 (en) 2004-06-08 2005-12-14 Axonyx, Inc. Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression
WO2008134618A2 (en) 2007-04-27 2008-11-06 The General Hospital Corporation Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders
WO2010117727A2 (en) 2009-03-30 2010-10-14 The General Hospital Corporation Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions
US20120225922A1 (en) 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
TW201717938A (zh) 2015-08-14 2017-06-01 Ｑｒ製藥股份有限公司 治療或預防急性腦部或神經損傷的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LAHIRI et al, "The Experimental Alzheimer's Disease Drug Posiphen [(+)-Pherserine] Lowers Amyloid-β Peptide Levels in Cell Culture and Mice", The Journal of Pharmaceology and Experimental Therapeutics (2007), Vol. 320, No.1, 386-396 *
LILJA et al, "Neurotrophic and Neuroprotective Actions of (-)- and (+)-Phenserine, Candidate Drugs for Alzheimer's Disease", PLoS ONE (2013), 8(1):e54887 *
MACCECCHINI et al, "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and tau-levels: target engagement, tolerability and pharmacokinetics in humans", J Neurol Neurosurg Psychiatry (2012); 83:894-902 *

Also Published As

Publication number Publication date
CA2994974A1 (en) 2017-02-23
CN107921024B (zh) 2021-09-10
TW201717938A (zh) 2017-06-01
JP6862446B2 (ja) 2021-04-21
EP3334425B1 (en) 2020-12-16
CA2994974C (en) 2024-04-09
JP2018523709A (ja) 2018-08-23
US20250000846A1 (en) 2025-01-02
DK3334425T3 (da) 2021-02-22
US20180228771A1 (en) 2018-08-16
CN107921024A (zh) 2018-04-17
EP3334425A1 (en) 2018-06-20
HK1253901A1 (en) 2019-07-05
US12042482B2 (en) 2024-07-23
WO2017030968A1 (en) 2017-02-23
AU2016309815A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
US20250000846A1 (en) Methods of treatment or prevention of acute brain or nerve injuries
Sivak The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease
Cheung et al. Neuroprotection in glaucoma: drug‐based approaches
AU2022265392B2 (en) Method and pharmaceutical composition for treating myopia
ES2989745T3 (es) Terapia de intervalos para el tratamiento de enfermedades oculares
JP2023116748A (ja) 眼疾患の処置方法
HK1253901B (en) Methods of treatment or prevention of acute brain or nerve injuries
AU2016223995B2 (en) Extract of Taiwanese propolis for treating ocular diseases
Sakamoto et al. Histological protection by donepezil against neurodegeneration induced by ischemia–reperfusion in the rat retina
US11759451B2 (en) Therapeutic potential of glycopyrrolate and mexiletine for nervous system injury
Tang et al. (-) clausenamide improves long-term potentiation impairment and attenuates apoptosis after transient middle cerebral artery occlusion in rats
US20230372282A1 (en) Method for treateing or preventing ischemic optic neuropathy
HK40002019A (zh) 用於治疗眼疾的方法
Famà et al. Effects of calcium antagonists in the treatment of ophthalmic postherpetic neuralgia
HK1250489B (en) Substances containing gold clusters and preparation method and use thereof
EP4648797A1 (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis
Kawasaki Anisocoria
Prodhan 2.7. Rho Kinase Inhibitor
Díaz-Hung et al. Beta Amyloid Peptides: Extracellular and Intracellular

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ANNOVIS BIO, INC.

Free format text: FORMER NAME(S): QR PHARMA

FGA Letters patent sealed or granted (standard patent)